Shares in Dunedin cancer diagnostic company Pacific Edge have taken off again on the back of positive news from the United States.
Since Pacific Edge announced on Thursday the granting of US patent protection over a new melanoma development, its shares have risen from 80c to trade around 95c yesterday, closing at 94c. Pacific Edge became one of the stock exchange's top performers last year.
Following a deluge of announcements of new contracts last year, the company's shares rose from 45c to hit $1.74 over 12 weeks, before trailing off to 65c recently.
